71 related articles for article (PubMed ID: 16724524)
21. [Parkinson's disease].
Jean-Luc H
Rev Prat; 2005 May; 55(10):1129-34. PubMed ID: 16097259
[No Abstract] [Full Text] [Related]
22. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
Blandini F; Greenamyre JT
Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
[TBL] [Abstract][Full Text] [Related]
23. The role of glutamate in the pathophysiology of Parkinson's disease.
Blandini F; Greenamyre JT; Nappi G
Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
[No Abstract] [Full Text] [Related]
24. When and how should treatment be started in Parkinson disease?
Lang AE
Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
[TBL] [Abstract][Full Text] [Related]
25. Continuous dopaminergic stimulation: clinical aspects and experimental bases.
Rodriguez-Oroz MC; Marin C; de Fabregues O
Neurologist; 2011 Nov; 17(6 Suppl 1):S30-7. PubMed ID: 22045323
[TBL] [Abstract][Full Text] [Related]
26. Updates in the medical management of Parkinson disease.
Fernandez HH
Cleve Clin J Med; 2012 Jan; 79(1):28-35. PubMed ID: 22219231
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacotherapy and guidelines].
Baas H
Pharm Unserer Zeit; 2006; 35(3):242-8. PubMed ID: 16724528
[No Abstract] [Full Text] [Related]
28. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
29. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
Kim HJ; Jeon BS; Jenner P
Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
[TBL] [Abstract][Full Text] [Related]
30. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
31. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
Schapira AH
Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
33. [Parkinson disease. Medical treatment].
Fénelon G
Presse Med; 1997 Sep; 26(28):1357-61. PubMed ID: 9365497
[No Abstract] [Full Text] [Related]
34. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological approaches to Parkinson's disease in the different phases of evolution.
Giovannini P; Piccolo I; Scigliano G; Caraceni T
J Neural Transm Suppl; 1986; 22():173-87. PubMed ID: 3097255
[TBL] [Abstract][Full Text] [Related]
36. Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
Chouza C; Buzó R; Scaramelli A; Romero S; de Medina O; Aljanati R; Dieguez E; Lisanti N; Gomensoro J
J Neural Transm Suppl; 2006; (70):427-31. PubMed ID: 17017563
[No Abstract] [Full Text] [Related]
37. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
Szczudlik A; Rudzińska M
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
[TBL] [Abstract][Full Text] [Related]
38. Myths and realities of continuous dopaminergic stimulation.
Pirtošek Z
Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
[TBL] [Abstract][Full Text] [Related]
39. Management of parkinsonism and treatment of associated complications.
Nutt JG
Curr Opin Neurol; 1995 Aug; 8(4):327-30. PubMed ID: 7582052
[TBL] [Abstract][Full Text] [Related]
40. Emerging drugs for levodopa-induced dyskinesia.
Al Dakheel A; Beaulieu-Boire I; Fox SH
Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
